Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

There were no significant differences between male and female patients with RRMS in terms of age, age at diagnosis, duration of disease or treatment, or total cholesterol or 25-hydroxyvitamin D3 levels.

Source: Demographic and Clinical Characteristics of Patients with RRMS and HCs. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Case-control study.

Case-control study

Compares people with an outcome against people without it, examining exposures.

Meta-analysis unclear · Single-blind reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This case: control study comprised two overlapping groups: a genetic polymorphism group (330 RRMS, 330 healthy controls (HCs)) and a miRNA group (25 glatiramer acetate (GA)-treated RRMS patients, 25 treatment-naïve RRMS patients, and 25 HCs): collected at the Ankara Bilkent City Hospital Neurology Polyclinic.

Source: Abstract.

In this single-blind observational study, two overlapping groups were established: the genetic polymorphism study group and the miRNA and ELISA study group.

Source: Methods.

The study participants were adults from an admixed Turkish population who were unrelated individuals.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Decoding the Potential Impact of Plasma hsa-miR-24-3p and hsa-miR-181 d-3p Expression, Plasma IFN-γ Levels, and IFNG rs2069727 T/C Genetic Variant on Multiple Sclerosis Risk and Glatiramer Acetate Treatment

Case-control study · Molecular Neurobiology · 2025

Original publication title

Decoding the Potential Impact of Plasma hsa-miR-24-3p and hsa-miR-181 d-3p Expression, Plasma IFN-γ Levels, and IFNG rs2069727 T/C Genetic Variant on Multiple Sclerosis Risk and Glatiramer Acetate Treatment

Mekselina Kalmaz; Semra Mungan; Birsen Can Demirdöğen

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Multiple sclerosis (MS) is an autoimmune neurodegenerative disorder, with relapsing: remitting MS (RRMS) being the most common subtype. Interferon-γ (IFN-γ) plays a dual role in MS pathogenesis. MicroRNAs (miRNAs) have emerged as potential diagnostic biomarkers. This study examined the effect of relative expression of hsa-miR-24-3p and hsa-miR-181d-3p, plasma IFN-γ levels, and the IFNG rs2069727 T/C variant on MS risk, evaluating their interrelationships and diagnostic potential. This case: control study comprised two overlapping groups: a genetic polymorphism group (330 RRMS, 330 healthy controls (HCs)) and a miRNA group (25 glatiramer acetate (GA)-treated RRMS patients, 25 treatment-naïve RRMS patients, and 25 HCs): collected at the Ankara Bilkent City Hospital Neurology Polyclinic.

The IFNG rs2069727 T/C variant did not display a statistically significant disparity between RRMS patients and HCs. Significantly elevated hsa-miR-24-3p and hsa-miR-181d-3p relative expression levels were observed in GA-treated and treatment-naïve RRMS patients compared to HCs. Conversely, age-adjusted plasma IFN-γ concentrations were markedly lower in GA-treated and treatment-naïve RRMS patients versus HCs. Individuals with low plasma IFN-γ levels (≤ 1.311 pg/mL) demonstrated significantly elevated hsa-miR-24-3p relative expression compared to the high IFN-γ group (> 1.311 pg/mL). Conversely, subjects with low hsa-miR-181d-3p levels (≤ 2.90) exhibited significantly higher plasma IFN-γ concentrations relative to those with high hsa-miR-181d-3p levels (> 2.90).

In the GA-treated group, EDSS negatively correlated with age-adjusted plasma IFN-γ. This study identified age-adjusted plasma IFN-γ, hsa-miR-24-3p, and hsa-miR-181d-3p expression as potential blood-based biomarkers for RRMS diagnosis and analyzed them alongside disability scores. The miRNAs in this study can be further evaluated as prospective therapeutic targets.

Authors’ abstract

Multiple sclerosis (MS) is an autoimmune neurodegenerative disorder, with relapsing: remitting MS (RRMS) being the most common subtype. Interferon-γ (IFN-γ) plays a dual role in MS pathogenesis. MicroRNAs (miRNAs) have emerged as potential diagnostic biomarkers. This study examined the effect of relative expression of hsa-miR-24-3p and hsa-miR-181d-3p, plasma IFN-γ levels, and the IFNG rs2069727 T/C variant on MS risk, evaluating their interrelationships and diagnostic potential. This case: control study comprised two overlapping groups: a genetic polymorphism group (330 RRMS, 330 healthy controls (HCs)) and a miRNA group (25 glatiramer acetate (GA)-treated RRMS patients, 25 treatment-naïve RRMS patients, and 25 HCs): collected at the Ankara Bilkent City Hospital Neurology Polyclinic.

The IFNG rs2069727 T/C variant did not display a statistically significant disparity between RRMS patients and HCs. Significantly elevated hsa-miR-24-3p and hsa-miR-181d-3p relative expression levels were observed in GA-treated and treatment-naïve RRMS patients compared to HCs. Conversely, age-adjusted plasma IFN-γ concentrations were markedly lower in GA-treated and treatment-naïve RRMS patients versus HCs. Individuals with low plasma IFN-γ levels (≤ 1.311 pg/mL) demonstrated significantly elevated hsa-miR-24-3p relative expression compared to the high IFN-γ group (> 1.311 pg/mL). Conversely, subjects with low hsa-miR-181d-3p levels (≤ 2.90) exhibited significantly higher plasma IFN-γ concentrations relative to those with high hsa-miR-181d-3p levels (> 2.90).

In the GA-treated group, EDSS negatively correlated with age-adjusted plasma IFN-γ. This study identified age-adjusted plasma IFN-γ, hsa-miR-24-3p, and hsa-miR-181d-3p expression as potential blood-based biomarkers for RRMS diagnosis and analyzed them alongside disability scores. The miRNAs in this study can be further evaluated as prospective therapeutic targets.

Publication and source details

Original title: Decoding the Potential Impact of Plasma hsa-miR-24-3p and hsa-miR-181 d-3p Expression, Plasma IFN-γ Levels, and IFNG rs2069727 T/C Genetic Variant on Multiple Sclerosis Risk and Glatiramer Acetate Treatment

Mekselina Kalmaz; Semra Mungan; Birsen Can Demirdöğen

Molecular Neurobiology · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100004410Türkiye Bilimsel ve Teknolojik Araştırma Kurumu121S345121S345121S345TOBB University of Economics and Technology

Open access funding provided by the Scientific and Technological Research Council of Türkiye (TÜBİTAK).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T04:50:17.345989+00:00

DOI: 10.1007/s12035-025-05027-9 · PMC12433355